Are you a researcher or care provider with an idea that could become a novel therapy or device to benefit patient care? Are you seeking more information on how to translate your ideas to the bedside? Hear from David Resnick, Partner at Nixon Peabody’s patent group and a thought leader on strategies to protect intellectual property. Learn more about TIDO, your Children’s partner in working to bring your ideas to reality.

Join us Wednesday, May 17 either virtually (Zoom details below) or in the Folkman Auditorium from 4:00-5:30 PM. Refreshments will be provided. Please indicate your interest by RSVP’ing here here.

Agenda

4:00-4:15 | Refreshments and Mingling
4:15-4:25 | Introductory Remarks
4:25-5:00 | Presentation
5:00-5:30 | Q & A

In Person Details
Time: 4:00-5:30PM
Location: Folkman Auditorium

Webinar Details
Time: 4:14-5:30PM
Zoom Link: Click Here
Passcode: 999960

Contact Ulysses Sallum, Director of Business Development, at Ulysses.Sallum@childrens.harvard.edu with any questions!

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care.

Sanofi iAwards initiative is a multi-institutional partnership program designed to support collaborations with academic investigators to accelerate innovative early stage, disease-relevant research towards the clinic. With this program, Sanofi aims to fund cutting-edge translational research that can contribute to our early-stage pipeline and ultimately benefit patients. Award winning proposals will receive:

  • $150,000 research funding including institutional direct and indirect costs for 12 months with up to 12 awards given in the 2023-2024 cycle
  • Sanofi R&D expertise and guidance

Sanofi’s main objective in creating the iAwards program is to convert successful and promising iAwards projects to sponsored research programs and subsequently create in-licensing and start-up opportunities with the potential to continuously enrich Sanofi’s early-stage portfolio.

Submission Process

Ideas must be submitted using the Pre-proposal template and submitted to TIDO.Alliances@childrens.harvard.edu before June 2, 2023 to ensure that your proposal is aligned with the scope and fulfills the application criteria of the call. Pre-proposals that are not validated by your institution TTO (for academic PIs) or do not fit with the guidelines (format, timeline, etc.) will not be evaluated. Please note that pre-proposals must not contain any confidential information or unpublished results and cannot include 3rd party collaborators other than those involved in the iDEA-iTECH Awards initiative.

Areas of Interest

  • Overall
    • New and actionable knowledge about disease relevant targets, pathways, and mechanisms
    • Early-stage compounds or biologics targeting novel disease mechanisms
    • New models for validating disease relevant targets
    • Novel therapeutic modalities
  • Immunology and Inflammation
  • Rare & Neurological Diseases
  • Gene Therapy
  • Oncology
  • Precision Medicine and Computational Biology

For more information on areas of interest, see the full call for proposals.

Deerfield has pledged up to $65 million with the goal of facilitating the translation and commercialization of novel biomedical research at Boston Children’s Hospital through a new collaboration called Blackfan Circle Innovations. Through Blackfan Circle, Boston Children’s Hospital scientists have the opportunity to submit therapeutic proposals for potential funding.

Deerfield will provide research funding and operational support in product development and commercialization to co-develop the jointly-selected research therapeutic candidates with the goal of achieving Investigational New Drug (IND) readiness. Successful projects that reach IND-enabled status may receive additional funding.

We would like to invite BCH investigators to begin the submission process to Blackfan Circle Innovations, the newly established entity created to accelerate research at BCH.

Areas of Interest:

  • Broad interest across all therapeutic areas and modalities
  • Early-stage projects with potential to progress to IND-enabled status, early clinical development, and human proof-of-concept

Proposal Process:

  • Proposal Concept Sheet
  • Letter of Intent
  • Full Proposal and Presentation

In order to engage initial interest with Blackfan Circle Innovations, TIDO encourages BCH investigators to submit one or more Proposal Concept Sheet(s), each of which will constitute a brief overview of the proposed project focusing on the areas listed below.

  • Genetic Evidence
  • Biologic Rationale
  • Preclinical Execution
  • Unmet Need
  • Clinical Development (if applicable)
  • Novelty/ Differentiation

A Proposal Concept Sheet submission template will be provided by TIDO. For more information on proposal submission to Blackfan Circle Innovations, a copy of the Proposal Concept Sheet, or questions related to the application process, please contact Sabrina Kamran, Strategic Alliance Manager at Sabrina.Kamran@childrens.harvard.edu.

If your Proposal Concept Sheet is selected for advancement, you will be asked to complete a Letter of Intent with a more detailed description of the proposed project. Finally, at the Full Proposal stage of evaluation, you will be asked to submit a detailed research plan and budget and meet with the Deerfield review team to discuss your proposal. Deerfield Discovery and Development experts will be available to consult with you on your proposal throughout the entire evaluation process.

Who Can Apply:

  • Full-time BCH Principal Investigators
  • Principal Investigators with faculty appointment who are subject to Boston Children’s policies regarding the conduct of research and ownership of intellectual property

Submissions:

Proposal Concept Sheets submitted to Blackfan Circle Innovations will be considered on a rolling basis, with operational and scientific guidance and support from TIDO during the submission process.